JP2024525239A - 化合物ｓｍｔｐ－７を含有する医薬組成物 - Google Patents

化合物ｓｍｔｐ－７を含有する医薬組成物 Download PDF

Info

Publication number
JP2024525239A
JP2024525239A JP2023563075A JP2023563075A JP2024525239A JP 2024525239 A JP2024525239 A JP 2024525239A JP 2023563075 A JP2023563075 A JP 2023563075A JP 2023563075 A JP2023563075 A JP 2023563075A JP 2024525239 A JP2024525239 A JP 2024525239A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
smtp
composition according
additive
basic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525239A5 (enExample
Inventor
ニシムラ、ナオコ
ハセガワ、ケイコ
ハスミ、ケイジ
Original Assignee
ジーシン ファーマシューティカルズ ホンコン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーシン ファーマシューティカルズ ホンコン リミテッド filed Critical ジーシン ファーマシューティカルズ ホンコン リミテッド
Publication of JP2024525239A publication Critical patent/JP2024525239A/ja
Publication of JP2024525239A5 publication Critical patent/JP2024525239A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023563075A 2021-04-20 2022-04-20 化合物ｓｍｔｐ－７を含有する医薬組成物 Pending JP2024525239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021070892 2021-04-20
JP2021070892 2021-04-20
PCT/US2022/025462 WO2022226013A1 (en) 2021-04-20 2022-04-20 Pharmaceutical composition comprising the compound smtp-7

Publications (2)

Publication Number Publication Date
JP2024525239A true JP2024525239A (ja) 2024-07-11
JP2024525239A5 JP2024525239A5 (enExample) 2025-04-30

Family

ID=81648879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563075A Pending JP2024525239A (ja) 2021-04-20 2022-04-20 化合物ｓｍｔｐ－７を含有する医薬組成物

Country Status (9)

Country Link
US (1) US20240238252A1 (enExample)
EP (1) EP4326258A1 (enExample)
JP (1) JP2024525239A (enExample)
KR (1) KR20230173129A (enExample)
CN (1) CN117279634A (enExample)
AU (1) AU2022262593A1 (enExample)
BR (1) BR112023021803A2 (enExample)
CA (1) CA3214630A1 (enExample)
WO (1) WO2022226013A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011004620A1 (ja) * 2009-07-06 2012-12-20 国立大学法人東京農工大学 細胞保護剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
EP1944027A4 (en) 2005-10-06 2009-08-19 Univ Tokyo Nat Univ Corp PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF NEPHRITIS AND METHOD OF MANUFACTURE THEREOF
EP2604697B1 (en) 2006-03-27 2015-07-01 Tokyo University of Agriculture and Technology TLO Triprenyl phenol compounds, process for their production and use as thrombolysis enhancer
WO2011125930A1 (ja) 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
AU2022275263A1 (en) * 2021-05-10 2023-11-09 Corxel Pharmaceuticals Hong Kong Limited Pharmaceutical composition for use in treating cerebral infarction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011004620A1 (ja) * 2009-07-06 2012-12-20 国立大学法人東京農工大学 細胞保護剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD COAGUL. FIBRINOLYS., vol. 25, JPN6026012011, 2014, pages 316 - 321, ISSN: 0005829019 *

Also Published As

Publication number Publication date
EP4326258A1 (en) 2024-02-28
WO2022226013A1 (en) 2022-10-27
AU2022262593A1 (en) 2023-11-02
CN117279634A (zh) 2023-12-22
US20240238252A1 (en) 2024-07-18
KR20230173129A (ko) 2023-12-26
BR112023021803A2 (pt) 2024-01-23
CA3214630A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
JP7082115B2 (ja) 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法
JP2024123126A (ja) Ｅｆｐの治療または低減方法
JP4466370B2 (ja) 過活動膀胱治療剤
US9107925B2 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
CN108472275A (zh) 治疗缺血性中风的组合物及方法
JP2010523696A (ja) 脳腫瘍を治療する方法
JPWO2011004620A1 (ja) 細胞保護剤
JP2023517566A5 (enExample)
KR20150027800A (ko) 경도 인지 장해의 예방 및/또는 치료제
EP4495122A1 (en) Artemisinin derivatives, preparation method therefor, and uses thereof
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
HK40105250A (zh) 包含化合物smtp-7的药物组合物
EP4176873A1 (en) Urinary symptom therapeutic agent
AU2012396942A2 (en) Use of pidotimod to treat psoriasis
JPWO2006004028A1 (ja) キノロン含有医薬組成物
JP7257091B2 (ja) 認知症の治療及び予防薬
US20080255238A1 (en) Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
TW202033186A (zh) 眼科用組成物
KR102832710B1 (ko) 당뇨병 또는 당뇨합병증의 치료를 위한 4-헥실레조르시놀의 용도
JP2020100576A (ja) 皮膚外用組成物
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
US20120277264A1 (en) Antithrombotic agent
US20210085627A1 (en) Methods of treating diseases and disorders using compositions comprising 18-hepe, 12-hepe, or combinations thereof
JP2020100575A (ja) 皮膚外用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240528

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331